The US neurostimulation device market will grow rapidly, driven by expanding approval of these devices for new indications, increasing demand for non-pharmaceutical treatments, and the growing need for replacement devices as previously implanted devices begin to reach the ends of their life spans.  Nevertheless, the COVID-19 pandemic will limit growth in the initial years of the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurostimulation devices in the US across a 10-year period.

The COVID-19 pandemic will negatively impact the US neurostimulation device market. 

Which types of procedures and device segments will be most impacted?

At what pace are neurostimulation device markets expected to recover?

Growing pressure on the US government to curb the opioid epidemic has drastically shifted the pain management landscape.

How have emerging policy changes affected the SCS device market landscape?

What factors are driving the development of neuromodulation devices for pain management?

How are competitors adapting to the increasing demand for nonpharmaceutical pain management?

Neurostimulation device implant procedures in the US are increasingly shifting towards nonhospital sites of service.

Which device segments will see the strongest site of service shift?

What are the procedural and reimbursement factors underlying the shift toward nonhospital facilities?

Medtronic has faced increasing challenges from emerging and established competitors in the neurostimulation device market.

How have Medtronic's shares changed in recent years, and which competitors have gained at its expense?

What are the factors that have driven the increased competitiveness within the SCS device market?

Table of contents

  • Neurostimulation Devices - Market Insights - United States

Author(s): Sophia Quraishi, BA

Sophia Quraishi is an analyst on the Medtech Insights team at Decision Resources Group and currently serves as the in-house expert in gastroenterology, open surgery, and liquid biopsy markets. Sophia has been instrumental in leveraging medical claims and hospital purchase order data for expanded new areas of investigation within her fields of expertise. Sophia holds a Bachelor's degree in Psychology with a specialization in Neuroscience from Columbia University in the City of New York.